Fosun Pharma (02196) Announces Proposed Spin-Off Listing for Fosun Adgenvax

Bulletin Express

Oct 28

On 28 October 2025, the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Fosun Pharma, Stock Code: 02196) approved a plan for the spin-off listing of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.* (Fosun Adgenvax) on The Stock Exchange of Hong Kong Limited. Fosun Adgenvax was established in July 2012 and is currently 70.08% owned by a Fosun Pharma subsidiary, with 17 other shareholders holding a combined 29.92% stake.

Fosun Adgenvax and its subsidiaries focus on research, development, production, and sales of vaccines for human use, having built technical platforms for both bacterial and viral vaccines. Several self-developed products—including rabies vaccines (Vero cell) for human use, trivalent and quadrivalent influenza virus lysate vaccines—are already marketed in Chinese mainland, and others are at various clinical trial stages. The planned spin-off is at a preliminary phase with no assurance on its final timetable or completion, and shareholders are advised to exercise caution when dealing in Fosun Pharma securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1112916581"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112916581\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112916581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-28 18:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112916581","market":"us","top_or_hot":-1,"title":"Fosun Pharma (02196) Announces Proposed Spin-Off Listing for Fosun Adgenvax","media":"Bulletin Express","content":"<p>On 28 October 2025, the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Fosun Pharma, Stock Code: 02196) approved a plan for the spin-off listing of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.* (Fosun Adgenvax) on The Stock Exchange of Hong Kong Limited. Fosun Adgenvax was established in July 2012 and is currently 70.08% owned by a Fosun Pharma subsidiary, with 17 other shareholders holding a combined 29.92% stake.</p>\n<p>Fosun Adgenvax and its subsidiaries focus on research, development, production, and sales of vaccines for human use, having built technical platforms for both bacterial and viral vaccines. Several self-developed products—including rabies vaccines (Vero cell) for human use, trivalent and quadrivalent influenza virus lysate vaccines—are already marketed in Chinese mainland, and others are at various clinical trial stages. The planned spin-off is at a preliminary phase with no assurance on its final timetable or completion, and shareholders are advised to exercise caution when dealing in Fosun Pharma securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma (02196) Announces Proposed Spin-Off Listing for Fosun Adgenvax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma (02196) Announces Proposed Spin-Off Listing for Fosun Adgenvax\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-28 18:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 28 October 2025, the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Fosun Pharma, Stock Code: 02196) approved a plan for the spin-off listing of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.* (Fosun Adgenvax) on The Stock Exchange of Hong Kong Limited. Fosun Adgenvax was established in July 2012 and is currently 70.08% owned by a Fosun Pharma subsidiary, with 17 other shareholders holding a combined 29.92% stake.</p>\n<p>Fosun Adgenvax and its subsidiaries focus on research, development, production, and sales of vaccines for human use, having built technical platforms for both bacterial and viral vaccines. Several self-developed products—including rabies vaccines (Vero cell) for human use, trivalent and quadrivalent influenza virus lysate vaccines—are already marketed in Chinese mainland, and others are at various clinical trial stages. The planned spin-off is at a preliminary phase with no assurance on its final timetable or completion, and shareholders are advised to exercise caution when dealing in Fosun Pharma securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1112916581","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112916581","pubTimestamp":1761648101,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 28 October 2025, the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Fosun Pharma, Stock Code: 02196) approved a plan for the spin-off listing of Fosun Adgenvax (Chengdu)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02196":"复星医药"},"translate_title":"复星医药(02196)公布复星Adgenvax建议分拆上市","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"On 28 October 2025, the board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (Fosun Pharma, Stock Code: 02196) approved a plan for the spin-off listing of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.* (Fosun Adgenvax) on The Stock Exchange of Hong Kong Limited. Fosun Adgenvax was established in July 2012 and is currently 70.08% owned by a Fosun Pharma subsidiary, with 17 other shareholders holding a combined 29.92% stake.\nFosun Adgenvax and its subsidiaries focus on research, development, production, and sales of vaccines for human use, having built technical platforms for both bacterial and viral vaccines. Several self-developed products—including rabies vaccines (Vero cell) for human use, trivalent and quadrivalent influenza virus lysate vaccines—are already marketed in Chinese mainland, and others are at various clinical trial stages. The planned spin-off is at a preliminary phase with no assurance on its final timetable or completion, and shareholders are advised to exercise caution when dealing in Fosun Pharma securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}